Baird analyst Brian Skorney reiterates Outperform rating and $66 price target on Neurocrine Biosciences (NASDAQ: NBIX), noting the company reported ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE